Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•12/10/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $673.1 million, versus $7.9 million year over year
- ➤Q3 net income $549.8 million, or $4.73 diluted EPS
- ➤Cash, equivalents and marketable securities reached $1.1 billion
- ➤First patient dosed in registrational Phase 3 DAYBreak CLL-306 trial
- ➤Sanofi milestone triggered $10 million payment for STAT6 degrader trial
Expert Statements
Arthur T. Sands, President and Chief Executive Officer of Nurix Therapeutics
“The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease.”
Arthur T. Sands, President and Chief Executive Officer of Nurix Therapeutics
“At the same time, Sanofi advanced our oral STAT6 degrader into the clinic, and we advanced the CBL-B inhibitor NX-1607 into Phase 1b expansion cohorts across four solid tumor indications.”
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study
Get started
Create a free account to read the full story.